Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Sales | 747,313 | 745,740 | 712,029 | 648,833 | 646,207 |
| Cost of Goods | 136,139 | 188,457 | 130,459 | 125,180 | 137,930 |
| Gross Profit | 611,174 | 557,283 | 581,570 | 523,653 | 508,277 |
| Operating Expenses | 449,906 | 443,847 | 461,577 | 435,371 | 481,928 |
| Operating Income | 161,407 | 113,893 | 120,452 | 88,462 | 27,279 |
| Interest Expense | 2,577 | 2,968 | 3,574 | 3,547 | 6,098 |
| Other Income | 10,809 | 23,516 | 15,258 | 20,632 | -1,854 |
| Pre-tax Income | 169,639 | 134,441 | 132,136 | 105,547 | 19,327 |
| Income Tax | 44,696 | 28,361 | 24,962 | 16,885 | -1,048 |
| Net Income Continuous | 124,943 | 106,080 | 107,174 | 88,662 | 20,375 |
| Net Income | $124,943 | $106,080 | $107,174 | $88,662 | $20,375 |
| EPS Basic Total Ops | 0.66 | 0.56 | 0.56 | 0.47 | 0.11 |
| EPS Basic Continuous Ops | 0.66 | 0.56 | 0.56 | 0.47 | 0.11 |
| EPS Diluted Total Ops | 0.65 | 0.55 | 0.55 | 0.46 | 0.10 |
| EPS Diluted Continuous Ops | 0.65 | 0.54 | 0.53 | 0.45 | 0.11 |
| EPS Diluted Before Non-Recurring Items | 0.72 | 0.74 | 0.77 | N/A | N/A |
| EBITDA(a) | $183,288 | $130,958 | $144,739 | $113,310 | $51,693 |